{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:48:35Z","timestamp":1778226515814,"version":"3.51.4"},"reference-count":59,"publisher":"Bentham Science Publishers Ltd.","issue":"2","funder":[{"DOI":"10.13039\/501100002322","name":"Coordination for Improvement of Higher Education Personnel CAPES\/PROEX","doi-asserted-by":"publisher","award":["23038.005848\/2018-31"],"award-info":[{"award-number":["23038.005848\/2018-31"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordination for Improvement of Higher Education Personnel CAPES\/PROEX","doi-asserted-by":"publisher","award":["0737\/2018"],"award-info":[{"award-number":["0737\/2018"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordination for Improvement of Higher Education Personnel CAPES\/PROEX","doi-asserted-by":"publisher","award":["88887.354370\/2019-00"],"award-info":[{"award-number":["88887.354370\/2019-00"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDDT"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>SARS-CoV-2 main protease (Mpro or 3CLpro) and papain-like protease (PLpro) are common viral targets for repurposed drugs to combat COVID-19 disease. Recently, several anti-depressants (such as fluoxetine, venlafaxine and citalopram) belonging to the Selective Serotonin Reuptake Inhibitors (SSRIs) and the Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) classes have been shown to in vitro inhibit viral replication.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Aim:<\/jats:title>\n<jats:p>Investigate a possible action of fluoxetine and derivatives on SARS-CoV-2 protease sites.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>molecular docking was performed using AutoDock Vina. Both proteases structures and different drugs conformations were used to explore the possibility of SARS-CoV-2 inhibition on a Mpro or PLpro related pathway.  Drug structures were obtained by optimization with the Avogadro software and MOPAC using PM6 method. Results were analysed on Discovery Studio Visualizer.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The results indicated that Mpro interacted in a thermodynamically favorable way with fluoxetine, venlafaxine, citalopram, atomoxetine, nisoxetine and norfluoxetine in the region of the active site, whether PLpro conformers did not come close to active site.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>In an in silico perspective, it is likely that the SSRIs and other anti-depressants could interact with Mpro and cause the enzyme to malfunction. Unfortunately, the same drugs did not present similar results on PLpro crystal, therefore no inhibition is expected on an in vitro trial. Anyway, in vitro test are necessary for the better understanding the links between SARS-CoV-2 proteases and anti-depressants.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570163819666221010115118","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T06:37:06Z","timestamp":1665556626000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["In Silico Analysis of the Antidepressant Fluoxetine and Related Drugs at\nSARS-CoV-2 Main Protease (Mpro) and Papain-like Protease (PLpro)"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3829-0595","authenticated-orcid":true,"given":"Jo\u00e3o Batista","family":"Teixeira Rocha","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Federal University of Santa Maria (UFSM), 97105-900, RS,\nBrazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0551-5957","authenticated-orcid":true,"given":"Pedro Jos\u00e9","family":"Tronco Pauletto","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Federal University of Santa Maria (UFSM), 97105-900, RS,\nBrazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Folorunsho Bright","family":"Omage","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Federal University of Santa Maria (UFSM), 97105-900, RS,\nBrazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2009-0555","authenticated-orcid":true,"given":"C\u00e1ssia Pereira","family":"Delgado","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Federal University of Santa Maria (UFSM), 97105-900, RS,\nBrazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9133-6102","authenticated-orcid":true,"given":"Pablo Andrei","family":"Nogara","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Federal University of Santa Maria (UFSM), 97105-900, RS,\nBrazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.3390\/pharmaceutics13091400","volume":"13","author":"Brunotte L.","year":"2021","unstructured":"Brunotte L.; Zheng S.; Mecate Z.A.; Combination therapy with fluoxetine and the nucleoside analog gs-441524 exerts synergistic antiviral effects against different sars-cov-2 variants in vitro. Pharmaceutics 2021,13(9),1400","journal-title":"Pharmaceutics"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3390\/microorganisms9020339","volume":"9","author":"Dechaumes A.","year":"2021","unstructured":"Dechaumes A.; Nekoua M.P.; Belouzard S.; Fluoxetine can inhibit SARS-CoV-2 in vitro. Microorganisms 2021,9(2),339","journal-title":"Microorganisms"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2000115","DOI":"10.1002\/minf.202000115","volume":"40","author":"Cavasotto C.N.","year":"2021","unstructured":"Cavasotto C.N.; Di Filippo J.I.; In silico drug repurposing for COVID\u201019: Targeting SARS\u2010CoV\u20102 proteins through docking and consensus ranking. Mol Inform 2021,40(1),2000115","journal-title":"Mol Inform"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"5735","DOI":"10.1080\/07391102.2020.1792344","volume":"39","author":"Koulgi S.","year":"2021","unstructured":"Koulgi S.; Jani V.; Uppuladinne M.; Drug repurposing studies targeting SARS-CoV-2: An ensemble docking approach on drug target 3C-Like Protease (3CLpro). J Biomol Struct Dyn 2021,39(15),5735-5755","journal-title":"J Biomol Struct Dyn"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"Pushpakom S.","year":"2019","unstructured":"Pushpakom S.; Iorio F.; Eyers P.A.; Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov 2019,18(1),41-58","journal-title":"Nat Rev Drug Discov"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s11655-020-3427-6","volume":"26","author":"Wei T.Z.","year":"2020","unstructured":"Wei T.Z.; Wang H.; Wu X.Q.; In silico screening of potential spike glycoprotein inhibitors of SARS-CoV-2 with drug repurposing strategy. Chin J Integr Med 2020,26(9),663-669","journal-title":"Chin J Integr Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1038\/s41467-020-17189-2","volume":"11","author":"Sadegh S.","year":"2020","unstructured":"Sadegh S.; Matschinske J.; Blumenthal D.B.; Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing. Nat Commun 2020,11(1),3518","journal-title":"Nat Commun"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1080\/07391102.2020.1844058","volume":"40","author":"Sharma S.","year":"2022","unstructured":"Sharma S.; Deep S.; In-silico drug repurposing for targeting SARS-CoV-2 main protease (M pro). J Biomol Struct Dyn 2022,40(7),3003-3010","journal-title":"J Biomol Struct Dyn"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"Ashburn T.T.","year":"2004","unstructured":"Ashburn T.T.; Thor K.B.; Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004,3(8),673-683","journal-title":"Nat Rev Drug Discov"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1038\/s41380-021-01021-4","volume":"26","author":"Hoertel N.","year":"2021","unstructured":"Hoertel N.; Rico M.S.; Vernet R.; Association between SSRI antidepressant use and reduced risk of intubation or death. Mol Psychiatry 2021,26(9),5199-5212","journal-title":"Mol Psychiatry"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"5199","DOI":"10.1038\/s41380-021-01021-4","volume":"26","author":"Hoertel N.","year":"2021","unstructured":"Hoertel N.; S&#xE1;nchez R.M.; Vernet R.; Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: Results from an observational study. Mol Psychiatry 2021,26,5199-5212","journal-title":"Mol Psychiatry"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1002\/cpt.2317","volume":"110","author":"Hoertel N.","year":"2021","unstructured":"Hoertel N.; S&#xE1;nchez R.M.; Gulbins E.; Association between FIASMAs and reduced risk of intubation or death in individuals hospitalized for severe COVID\u201019: An observational multicenter study. Clin Pharmacol Ther 2021,110(6),1498-1511","journal-title":"Clin Pharmacol Ther"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1101\/2021.10.25.21265218","volume":"11","author":"Rauchman S.H.","year":"2021","unstructured":"Rauchman S.H.; Mendelson S.G.; Rauchman C.; Kasselman L.J.; Pinkhasov A.; Reiss A.B.; Ongoing use of SSRIs and the hospital course of COVID-19 patients: A retrospective outcome analysis. J Clin Med 2021,11(1),70","journal-title":"J Clin Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2174\/138920006775541561","volume":"7","author":"Mandrioli R.","year":"2006","unstructured":"Mandrioli R.; Forti G.; Raggi M.; Fluoxetine metabolism and pharmacological interactions: The role of cytochrome p450. Curr Drug Metab 2006,7(2),127-133","journal-title":"Curr Drug Metab"},{"key":"ref=15","first-page":"13","volume":"53","author":"DeVane C.L.","year":"1992","unstructured":"DeVane C.L.; Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 1992,53(2)(Suppl.),13-20","journal-title":"J Clin Psychiatry"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/minf.201400192","author":"Kaserer T.","year":"2015","unstructured":"Kaserer T.; H&#xE7;ferl M.; M&#xFC;ller K.; Elmer S.; Ganzera M.; J&#xE4;ger W.; In silico predictions of drug \u2013 drug interactions caused by CYP1A2, 2C9 and 3A4 inhibition \u2013 A comparative study of virtual screening performance. Mol Inform 2015,431-457","journal-title":"Mol Inform"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/1574887111308010002","volume":"8","author":"Ghanizadeh A.","year":"2013","unstructured":"Ghanizadeh A.; Freeman R.D.; Berk M.; Efficacy and adverse effects of venlafaxine in children and adolescents with ADHD: A systematic review of non-controlled and controlled trials. Rev Recent Clin Trials 2013,8(1),2-8","journal-title":"Rev Recent Clin Trials"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1001\/jamainternmed.2014.1891","volume":"174","author":"Joffe H.","year":"2014","unstructured":"Joffe H.; Guthrie K.A.; LaCroix A.Z.; Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: A randomized clinical trial. JAMA Intern Med 2014,174(7),1058-1066","journal-title":"JAMA Intern Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"5890","DOI":"10.1038\/s41598-021-85049-0","volume":"11","author":"Zimniak M.","year":"2021","unstructured":"Zimniak M.; Kirschner L.; Hilpert H.; The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue. Sci Rep 2021,11(1),5890","journal-title":"Sci Rep"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"755600","DOI":"10.3389\/fphar.2021.755600","volume":"12","author":"Fred S.M.","year":"2022","unstructured":"Fred S.M.; Kuivanen S.; Ugurlu H.; Casarotto P.C.; Levanov L.; Saksela K.; Antidepressant and antipsychotic drugs reduce viral infection by SARS-CoV-2 and fluoxetine show antiviral activity against the novel variants in vitro. Front Pharmacol 2022,12,755600","journal-title":"Front Pharmacol"},{"key":"ref=21","first-page":"1689","volume":"53","author":"Egziabher T.B.G.","year":"2020","unstructured":"Egziabher T.B.G.; Edwards S.; Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine 2 and itraconazole effectively impairs SARS-CoV-2 infection in vitro. Africa\u2019s potential. Ecol Intensif Agric 2020,53(9),1689-1699","journal-title":"Ecol Intensif Agric"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"100142","DOI":"10.1016\/j.xcrm.2020.100142","volume":"1","author":"Carpinteiro A.","year":"2020","unstructured":"Carpinteiro A.; Edwards M.J.; Hoffmann M.; Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells. Cell Rep Med 2020,1(8),100142","journal-title":"Cell Rep Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1080\/22221751.2020.1829082","volume":"9","author":"Schloer S.","year":"2020","unstructured":"Schloer S.; Brunotte L.; Goretzko J.; Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine. Emerg Microbes Infect 2020,9(1),2245-2255","journal-title":"Emerg Microbes Infect"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1176\/ajp.154.7.963","volume":"154","author":"Amsterdam J.D.","year":"1997","unstructured":"Amsterdam J.D.; Fawcett J.; Quitkin F.M.; Fluoxetine and norfluoxetine plasma concentrations in major depression: A multicenter study. Am J Psychiatry 1997,154(7),963-969","journal-title":"Am J Psychiatry"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/00004714-199106000-00024","volume":"11","author":"Pato M.T.","year":"1991","unstructured":"Pato M.T.; Murphy D.L.; Devane L.C.; Sustained plasma concentrations of fluoxetine and\/or norfluoxetine four and eight weeks after fluoxetine discontinuation. J Clin Psychopharmacol 1991,11(3),224-225","journal-title":"J Clin Psychopharmacol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/00004850-199300810-00004","volume":"8","author":"Norman T.R.","year":"1993","unstructured":"Norman T.R.; Gupta R.K.; Burrows G.D.; Parker G.; Judd F.K.; Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine. Int Clin Psychopharmacol 1993,8(1),25-30","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000089825","volume":"52","author":"Ferguson J.M.","year":"2006","unstructured":"Ferguson J.M.; Hill H.; Pharmacokinetics of fluoxetine in elderly men and women. Gerontology 2006,52(1),45-50","journal-title":"Gerontology"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2165\/00003495-198937020-00003","volume":"37","author":"Lancaster S.G.","year":"1989","unstructured":"Lancaster S.G.; Gonzalez J.P.; Lofepramine. Drugs 1989,37(2),123-140","journal-title":"Drugs"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"592289","DOI":"10.3389\/fchem.2020.592289","volume":"8","author":"Ibrahim T.M.","year":"2020","unstructured":"Ibrahim T.M.; Ismail M.I.; Bauer M.R.; Bekhit A.A.; Boeckler F.M.; Supporting SARS-CoV-2 papain-like protease drug discovery: In silico methods and benchmarking. Front Chem 2020,8(November),592289","journal-title":"Front Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41467-021-21060-3","volume":"12","author":"Osipiuk J.","year":"2021","unstructured":"Osipiuk J.; Azizi S.A.; Dvorkin S.; Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Nat Commun 2021,12(1),743","journal-title":"Nat Commun"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","volume":"587","author":"Shin D.","year":"2020","unstructured":"Shin D.; Mukherjee R.; Grewe D.; Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 2020,587(7835),657-662","journal-title":"Nature"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1038\/s41467-021-23313-7","volume":"12","author":"Amporndanai K.","year":"2021","unstructured":"Amporndanai K.; Meng X.; Shang W.; Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives. Nat Commun 2021,12(1),3061","journal-title":"Nat Commun"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.abf1611","volume":"371","author":"Qiao J.","year":"2021","unstructured":"Qiao J.; Li Y.S.; Zeng R.; SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model. Science 2021,371(6536),1374-1378","journal-title":"Science"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41598-022-06104-y","volume":"12","author":"Lewis D.S.M.","year":"2022","unstructured":"Lewis D.S.M.; Ho J.; Wills S.; Aloin isoforms (A and B) selectively inhibits proteolytic and deubiquitinating activity of Papain Like Protease (PLpro) of SARS-CoV-2 in vitro. Sci Rep 2022,12(1),2145","journal-title":"Sci Rep"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cytogfr.2019.06.001","volume":"48","author":"Woo B.","year":"2019","unstructured":"Woo B.; Baek K.H.; Regulatory interplay between deubiquitinating enzymes and cytokines. Cytokine Growth Factor Rev 2019,48,40-51","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"623971","DOI":"10.3389\/fchem.2020.623971","volume":"8","author":"Pitsillou E.","year":"2020","unstructured":"Pitsillou E.; Liang J.; Ververis K.; Lim K.W.; Hung A.; Karagiannis T.C.; Identification of small molecule inhibitors of the deubiquitinating activity of the SARS-CoV-2 papain-like protease: in silico molecular docking studies and in vitro enzymatic activity assay. Front Chem 2020,8,623971","journal-title":"Front Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"15199","DOI":"10.1128\/JVI.79.24.15199-15208.2005","volume":"79","author":"Lindner H.A.","year":"2005","unstructured":"Lindner H.A.; Fotouhi A.N.; Lytvyn V.; Lachance P.; Sulea T.; M&#xE9;nard R.; The papain-like protease from the severe acute respiratory syn-drome coronavirus is a deubiquitinating enzyme. J Virol 2005,79(24),15199-15208","journal-title":"J Virol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1021\/acs.jproteome.0c00779","volume":"19","author":"Franc&#xE9;s M.A.","year":"2020","unstructured":"Franc&#xE9;s M.A.; Hognon C.; Miclot T.; Molecular basis of SARS-CoV-2 infection and rational design of potential antiviral agents: Modeling and simulation approaches. J Proteome Res 2020,19(11),4291-4315","journal-title":"J Proteome Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"D1202","DOI":"10.1093\/nar\/gkv951","volume":"44","author":"Kim S.","year":"2016","unstructured":"Kim S.; Thiessen P.A.; Bolton E.E.; PubChem substance and compound databases. Nucleic Acids Res 2016,44(D1),D1202-D1213","journal-title":"Nucleic Acids Res"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/jcc","volume":"32","author":"Oleg T.A.J.O.","year":"2012","unstructured":"Oleg T.A.J.O.; AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading OLEG. J Comput Chem 2012,32,174-182","journal-title":"J Comput Chem"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2100028","DOI":"10.1002\/minf.202100028","volume":"40","author":"Nogara P.A.","year":"2021","unstructured":"Nogara P.A.; Omage F.B.; Bolzan G.R.; In silico studies on the interaction between mpro and PLpro from SARS\u2010CoV\u20102 and ebselen, its metabolites and derivatives. Mol Inform 2021,40(8),2100028","journal-title":"Mol Inform"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"Pettersen E.F.","year":"2004","unstructured":"Pettersen E.F.; Goddard T.D.; Huang C.C.; UCSF Chimera?A visualization system for exploratory research and analysis. J Comput Chem 2004,25(13),1605-1612","journal-title":"J Comput Chem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1758-2946-4-17","volume":"4","author":"Hanwell M.D.","year":"2012","unstructured":"Hanwell M.D.; Curtis D.E.; Lonie D.C.; Vandermeersch T.; Zurek E.; Hutchison G.R.; Avogadro: An advanced semantic chemical editor, visualization, and analysis platform. J Cheminform 2012,4(1),17","journal-title":"J Cheminform"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00894-007-0233-4","volume":"13","author":"Stewart J.J.P.","year":"2007","unstructured":"Stewart J.J.P.; Optimization of parameters for semiempirical methods V: Modification of NDDO approximations and application to 70 elements. J Mol Model 2007,13(12),1173-1213","journal-title":"J Mol Model"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"e11955","DOI":"10.1371\/journal.pone.0011955","volume":"5","author":"Chang M.W.","year":"2010","unstructured":"Chang M.W.; Ayeni C.; Breuer S.; Torbett B.E.; Virtual screening for HIV protease inhibitors: A comparison of AutoDock 4 and Vina. PLoS One 2010,5(8),e11955","journal-title":"PLoS One"},{"key":"ref=46","author":"Case D.A.","unstructured":"Case D.A.; Aktulga H.M.; Belfon K.;  Amber 2021 Available from 2021","journal-title":"Amber 2021"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0074-7696(08)60693-2","volume":"127","author":"Guern J.","year":"1991","unstructured":"Guern J.; Felle H.; Mathieu Y.; Kurkdjian A.; Regulation of intracellular pH in eukaryotic Cells. Int Rev Cytol 1991,127(C),111-173","journal-title":"Int Rev Cytol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"9934","DOI":"10.1021\/jp904306b","volume":"113","author":"Garrido E.M.","year":"2009","unstructured":"Garrido E.M.; Garrido J.; Calheiros R.; Marques M.P.M.; Borges F.; Fluoxetine and norfluoxetine revisited: New insights into the electrochem-ical and spectroscopic properties. J Phys Chem A 2009,113(36),9934-9944","journal-title":"J Phys Chem A"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1021\/ci100275a","volume":"51","author":"Hou T.","year":"2011","unstructured":"Hou T.; Wang J.; Li Y.; Wang W.; Assessing the performance of the MM\/PBSA and MM\/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model 2011,51(1),69-82","journal-title":"J Chem Inf Model"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1002\/jcc.23095","volume":"33","author":"Oehme D.P.","year":"2012","unstructured":"Oehme D.P.; Brownlee R.T.C.; Wilson D.J.D.; Effect of atomic charge, solvation, entropy, and ligand protonation state on MM-PB(GB)SA binding energies of HIV protease. J Comput Chem 2012,33(32),2566-2580","journal-title":"J Comput Chem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1080\/07391102.2020.1831610","volume":"40","author":"Paul A.S.","year":"2020","unstructured":"Paul A.S.; Islam R.; Parves M.R.; Cysteine focused covalent inhibitors against the main protease of SARS-CoV-2. J Biomol Struct Dyn 2020,40(4),1639-1658","journal-title":"J Biomol Struct Dyn"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"6032","DOI":"10.1039\/c3cs60055f","volume":"42","author":"Yin C.","year":"2013","unstructured":"Yin C.; Huo F.; Zhang J.; Thiol-addition reactions and their applications in thiol recognition. Chem Soc Rev 2013,42(14),6032-6059","journal-title":"Chem Soc Rev"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1039\/C4PY00339J","volume":"5","author":"Lowe A.B.","year":"2014","unstructured":"Lowe A.B.; Thiol\u2013ene &#x201C;click&#x201D; reactions and recent applications in polymer and materials synthesis: A first update. Polym Chem 2014,5(17),4820-4870","journal-title":"Polym Chem"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.cbpa.2020.04.017","volume":"58","author":"Ochtrop P.","year":"2020","unstructured":"Ochtrop P.; Hackenberger C.P.R.; Recent advances of thiol-selective bioconjugation reactions. Curr Opin Chem Biol 2020,58,28-36","journal-title":"Curr Opin Chem Biol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/cmdc.202000791","volume":"16","author":"Srinivasan B.","year":"2021","unstructured":"Srinivasan B.; Explicit treatment of non\u2010michaelis\u2010menten and atypical kinetics in early drug discovery**. ChemMedChem 2021,16(6),899-918","journal-title":"ChemMedChem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.crstbi.2020.12.001","volume":"3","author":"Rajpoot S.","year":"2021","unstructured":"Rajpoot S.; Alagumuthu M.; Baig M.S.; Dual targeting of 3CLpro and PLpro of SARS-CoV-2: A novel structure-based design approach to treat COVID-19. Curr Res Struct Biol 2021,3(3),9-18","journal-title":"Curr Res Struct Biol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"e9965","DOI":"10.7717\/peerj.9965","volume":"8","author":"Kouznetsova V.L.","year":"2020","unstructured":"Kouznetsova V.L.; Zhang A.; Tatineni M.; Miller M.A.; Tsigelny I.F.; Potential COVID-19 papain-like protease PL pro inhibitors: Repurposing FDA-approved drugs. PeerJ 2020,8,e9965","journal-title":"PeerJ"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"100038","DOI":"10.1016\/j.crphar.2021.100038","volume":"2","author":"Verma D.","year":"2021","unstructured":"Verma D.; Mitra D.; Paul M.; Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PLpro and Mpro\/3CLpro: Molecular docking and simulation studies of three pertinent medicinal plant natural components. Curr Res Pharmacol Drug Disc 2021,2(June),100038","journal-title":"Curr Res Pharmacol Drug Disc"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"10693","DOI":"10.3390\/ijms221910693","volume":"22","author":"Zrieq R.","year":"2021","unstructured":"Zrieq R.; Ahmad I.; Snoussi M.; Tomatidine and patchouli alcohol as inhibitors of SARS-CoV-2 enzymes (3CLpro, PLpro and NSP15) by molecular docking and molecular dynamics simulations. Int J Mol Sci 2021,22(19),10693","journal-title":"Int J Mol Sci"}],"container-title":["Current Drug Discovery Technologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570163819666221010115118","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/209771\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570163819666221010115118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T08:34:59Z","timestamp":1679906099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/209771\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570163819666221010115118","relation":{},"ISSN":["1570-1638"],"issn-type":[{"value":"1570-1638","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e101022209771"}}